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PPECIAL ARTICLE
evelopment of Cardiovascular Drugs
he U.S. Regulatory Milieu From
he Perspective of a Participating Nonregulator
effrey S. Borer, MD
ew York, New York
The Food and Drug Administration (FDA) is responsible for assuring that drugs, devices,
and biologicals available in the U.S. are effective and acceptably safe for their intended uses.
Both law and regulation define the procedures to be followed by the FDA in judging the
effectiveness and safety of therapies. The FDA comprises a cadre of highly skilled public
servants who receive and evaluate all data collected by the manufacturer during therapy, not
just the portion that reaches publication. To assist in reaching final conclusions about
approvability, the FDA can empanel legally constituted advisory committees and external
consultants when the need is perceived for additional specific scientific/technical expertise and
substantial experience in clinical practice. Evidentiary standards for marketing approval of
drugs, biologicals, and devices generally require direct demonstration of clinical benefit, rather
than inferences drawn from “surrogate” pharmacologic/device-mediated effects, sufficient
exposure to enable a reasonable assessment of countervailing risk, consideration of specific
design elements in the pivotal clinical trials (including prespecified hypotheses [implicitly
incorporated in “primary end points”], rigorous plans for statistical analyses, and so on), and
assessment of persistence of effectiveness and associated stability of safety over time. Finally,
sufficient information must be available so that practitioners can receive written instructions
for use (the label) adequate to support the likelihood that recipients of the therapy will receive
the expected benefits within the envelope of the stated risks. This article will discuss and
expand on these issues, with examples. (J Am Coll Cardiol 2004;44:2285–92) © 2004 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.059the American College of Cardiology Foundation
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the Food and Drug Administration (FDA) is responsible
or ensuring that drugs, devices, and biologicals available in
he U.S. are effective and acceptably safe for their intended
ses. At first glance, the bases for assessing effectiveness and
afety might seem intuitively obvious; indeed, operational
efinitions for effectiveness exist and are discussed subse-
uently. However, both conceptually and in regulatory
onsiderations, effectiveness and safety are inextricably in-
ertwined: acceptable safety must be judged in relation to
he importance of the benefit, a subjective assessment, and
o the availability of alternative therapy.
The law requires that, before therapeutic availability by
rescription or “over the counter” without prescription, the
DA must apply a benefit/risk standard to approve any new
rug (in this context, a product [usually but not necessarily
ynthetic] claiming health benefits from diagnosis or treat-
ent based on direct or indirect interaction with interme-
iary metabolism of the beneficiary), any device (a synthetic
roduct claiming similar benefit from physical interaction
ith the beneficiary), or any biological (a derivative or
roduct of a living organism other than its donor or, if
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Manuscript received May 21, 2004, accepted July 24, 2004.utologous, undergoing substantial processing before ad-
inistration). The FDA’s approval is based on evaluation of
New Drug Application, Pre-Marketing Approval, or
iologics Licensing Application from the sponsor (pro-
ucer) supporting its use. The application includes a pro-
osed label describing the product’s characteristics and
irections for use. This must also be approved by the FDA.
efore any new therapeutic can be studied in people, the
reclinical pharmacology/biology/actions, the general out-
ine of the proposed human studies, and the development
lan must be described in an Investigational New Drug
pplication for human studies (drugs, biologicals) or an
nvestigational Device Exemption for devices. The FDA
an prevent any or all of the proposed human studies if it
erceives safety concerns. During development and after
pproval, the FDA continually reviews and, if necessary,
tops studies or withdraws approval on the basis of adverse
vents (AEs), focusing especially on AEs meeting an oper-
tional definition of seriousness (serious [S]AEs). Allowable
E reporting intervals are strictly defined and enforced.
Riding herd on this effort is a Herculean task, in part
ecause of the rigorous scope of FDA reviews: all data
ollected by the manufacturer must be tabulated, submitted
o, and evaluated by the FDA. Although it is not necessary
or the FDA to review each source document (raw data),
hese must be available for audit/sampling. Evidence of
omplete and appropriate data collection must be provided
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Legal Regulation of Cardiovascular Drugs December 21, 2004:2285–92rom properly documented audits; “Good Clinical Practice,”
Good Laboratory Practice,” and “Good Manufacturing
ractice” standards must be employed in all research upon
hich FDA approval is based. By federal regulation, ap-
roval requires evidence of efficacy from adequate and
ell-controlled clinical studies, as well as safety acceptable
or the intended use defined from adequate exposure. Until
997, the plural “studies” was generally interpreted as
equiring at least two independent clinical trials. However,
y that time, progressively larger clinical trials had emerged,
ome focused on major adverse outcomes (death, stroke)
hat rendered study repetition ethically tenuous and/or
mpractical. Although the FDA accepted single persuasive
rials as a basis for approval in such cases, the 1997 law
xplicitly provides FDA authority in certain circumstances
o approve a therapy based on a single trial if adequate
confirmatory evidence” is available; the nature of the
onfirmatory evidence is not legally specified. The law also
equires performance of all tests of safety that are “reason-
bly applicable.”
This summary of approval requirements masks far more
omplex FDA judgments based on principles often very
ifferent from those that influence unfettered academic
esearch or clinical practice. The scientific method underlies
roblem solving in each area, but the latitude permitted in
nterpreting the results of scientific inquiry differs widely in
he three circumstances and is most stringent in the area of
herapeutics regulation.
This article describes my perception of some of these
imitations on interpretation. In so doing, it aims to eluci-
ate the process and principles by which cardiovascular
herapeutics and, most specifically, cardiovascular drugs are
pproved. The same overarching principles apply to ap-
roval of devices and biologicals that are increasingly im-
ortant in cardiovascular therapy, although characteristics
pecific to these other modalities impose unique limitations,
hich I will briefly review.
ACKGROUND
wenty-seven years ago, as a young Senior Investigator and
ead of Nuclear Cardiology at the National Heart, Lung,
nd Blood Institute (National Institutes of Health [NIH],
ethesda, Maryland), I was offered the opportunity to join
he Cardio-Renal Drugs Advisory Committee of the FDA
hen more senior NIH investigators were unavailable. As a
esult, for three decades, I have been continually involved in
n extraordinarily gratifying professional activity, serving
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AE  adverse event
ECG  electrocardiogram/electrocardiographic
FDA  Food and Drug Administrationhree separate terms on the Advisory Committee, each iulminated by terms as Committee Chairman, with service
s FDA Consultant during the intervening periods. In
ecent years, I have also acted as a guest member of the
irculatory System Devices Panel and the Biological Re-
ponse Modifiers Committee. From these activities, I have
earned about the unique discipline of therapeutics develop-
ent as modulated by regulatory principle, about clinical
harmacology, and about evidence evaluation, all from full
ata sets and primary sources far more complete than those
hat reach publication. (As suggested by Peter Medawar [via
lvan Feinstein], “. . . the careful organization given to the
ublished material does not reflect the way things hap-
ened. . . . After conquering [his/her] ignorance, the scien-
ist . . . may be reluctant to discuss how much ignorance”
eeded to be overcome (1); to the FDA, information on the
gnorance is also important.) Most importantly, though, I
ave had the unique satisfaction of participating in deliber-
tions that have overwhelming implications for the health of
he American people. This has been undertaken in conjunc-
ion with FDA officials who manifest extraordinary dedica-
ion, skill, and professionalism in assimilating, evaluating,
nd acting on an overwhelming mass of data in order to
alance the need of guarding the public health with timely
pproval (or rejection) of new therapeutics, meet the re-
uirements of scientific rigor, and provide fairness to com-
ercial sponsors. To all of these men and women, we each
we incalculable appreciation and admiration.
ersonnel: Officials, Advisors, and Consultants. The
DA comprises full-time experts in basic and preclinical
harmacology, clinical pharmacology, toxicology, statistics,
nd more. Most have previous clinical and/or research
xperience. After several years of reviewing Investigational
ew Drug/New Drug Applications, Pre-Marketing Ap-
roval, or Biologics Licensing Applications and the associ-
ted literature, these officials are highly knowledgeable
egarding the therapeutic areas under their purview (includ-
ng, for the Cardio-Renal Drugs Division, hypertension,
schemic heart disease, heart failure, arrhythmia, renal
isease, and pulmonary hypertension). When appropriate,
hey can call on the expertise of other FDA Divisions and
enters. What, then, is the need for Advisors and Consult-
nts? Primarily, to provide perspective gained from ongoing
ontemporary clinical and consumer experience, generally
ot available from full-time regulators because of their
orkload. Also, although FDA officials review and analyze
assive amounts of data, they do not produce the data;
alue is gained from the perspective of Advisors involved in
esearch like that under review.
he FDA and clinical practice. The FDA clearly plays a
undamental role in defining medical practice. However,
hough FDA decisions determine the pharmaceutical, de-
ice, and biological therapies (and many of the diagnostic
ools) available for patient care, these decisions refer only to
ses the sponsor proposes for marketing. In this sense, the
DA is a reactive body. Although the FDA is increasingly
nvolved with the details of developing therapeutics and
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December 21, 2004:2285–92 Legal Regulation of Cardiovascular Drugsften influences decisions about specific components of trial
esign such as outcome measures, it does not initiate
herapeutics development. More importantly, the FDA is
ot more broadly charged with definition of practice stan-
ards. Therapeutics approval and labeling define the benefit
the “indication”) that can generally be expected from
herapy, the characteristics of patients who can generally be
xpected to benefit, the administration regimen(s) likely to
rovide the benefit with acceptable relation to risk, and the
dverse experiences that may be associated with using the
herapy. Approvals are generally conservative: they focus
nly on one or more very carefully defined indication(s)
upported by well-designed clinical trials that provide sta-
istically persuasive evidence. Thus, evidentiary standards
or FDA approval imply a certain degree of scientific and
tatistical rigor. However, except when safety considerations
esult in the recommendation for use only if safer therapies
re intolerable or inadequate to provide the desired benefit,
r when study designs and results clearly support a sponsor-
ubmitted claim of superiority of one therapy over another,
he FDA does not prioritize among approved treatments for
given indication. The FDA does not recommend the use
f any specific therapy, does not comment on the relative
ost of different treatments, and does not sanction the use of
reatments outside the labeled indications or doses, but it
oes sanction sponsors who advertise outside the approved
abel. Recommendations for treatment and the prioritiza-
ion of therapies are the purview of professional societies or
guidelines” panels, generally comprising small groups of
xperienced clinicians/researchers with expertise in a specific
isease area, whose consensus recommendations are usually
ased on personal experience and published literature rather
han on the far more complete data available to the FDA,
nd who are not held to any predetermined standard of
tatistical or scientific rigor. Because patients must receive
he best possible care despite recognized deficiencies in
upporting data, consensus panels function in part to pro-
ide reasonable recommendations when rigorously defined
upporting data are not available. Thus, their function is
undamentally different from that of the FDA. It is entirely
onceivable (and regularly true) that “guidelines” include
ecommendations for use of drugs in settings and for
ndications not considered and sometimes even specifically
ejected by the FDA. Thus, the occasional argument by
ponsors seeking new indications for already approved drugs
hat “the horse is out of the barn,” meaning that clinical
ractice has moved beyond the FDA, generally has little
mpact on approval decisions. Because of the FDA’s legal
andate and the legal implications of its decisions, the
DA must require well-established evidentiary standards
or its imprimatur. Sanctions on physicians are not the
esponsibility of either the FDA or consensus panels, but
ather of the courts and, increasingly, of third-party payers;
ometimes such sanctions are based on the use of drugs or
ther treatments for “off-label” indications (i.e., to achieve
enefits not confirmed by the FDA). oUNDAMENTAL PRINCIPLES
videntiary standards. For approval, drugs must provide
ne or more specifically defined benefits, benefits must
utweigh associated risks, and instructions for use must
dequately inform legally constituted prescribers. Although
he potential cost reduction in drug development that could
esult from using “surrogate end points” is currently subject
o considerable discussion among drug developers and
cademic researchers, experience in cardiovascular medicine
as taught caution in relying on surrogates to predict
linical benefit. An illustration of the pitfalls associated with
urrogates is provided by the Cardiac Arrhythmia Suppres-
ion Trial (CAST) (2), which demonstrated that anti-
rrhythmic therapy applied after myocardial infarction to
uppress premature ventricular contractions (believed to be
athophysiologically similar to and predictive of lethal
rrhythmias) resulted in greater mortality than withholding
uch treatment. Thus, with the single exception of hyper-
ension relief (a surrogate for vascular event reduction), the
ardio-Renal Division requires that clinical benefit, not an
ffect on a surrogate end point, must be demonstrated by
irect measurement. (Low-density lipoprotein cholesterol
owering, a surrogate for atherosclerosis reduction and
avorable effects on acute myocardial infarction and survival,
s an accepted basis for approval by the FDA’s Metabolic-
ndocrine Division, which also recognizes decreases in
lycosylated hemoglobin level and blood glucose control as
easures of diabetes control that support approval.) Clinical
enefits fall into two broad categories: 1) reduction in
othersome symptoms (“feeling better”); and 2) increased
urvival duration and/or reduction in generally recognized
ajor morbid events. Clinical benefits must be distin-
uished from pharmacologic effects that may underlie, may
e expected to lead to, or may vary with the benefits. For
everal reasons, pharmacologic effects are generally not
cceptable bases for approval, even if there is a strongly held
elief about the relation between a pharmacologic effect and
clinical benefit. These include, first, that almost all drugs
ave multiple pharmacologic effects; we may not understand
he clinical impact of some and may not even be aware of
thers. Research and development tends to focus on phar-
acologic effects believed likely to underlie clinical effects,
ot on those for which such a relation is not perceived. Of
ourse, no evaluation can be undertaken of pharmacologic
ffects not recognized to exist; however, the clinical effect of
drug is the net effect of all its pharmacologic effects,
hether understood, misunderstood, or unknown. Only a
irect measurement of clinical effect integrates the impact of
ll pharmacologic effects (3,4). For example, angiotensin-
onverting enzyme (ACE) inhibitors are known to have at
east 10 pharmacologic effects. For several ACE inhibitors,
linical trials show that the net effect is beneficial for most
atients with hypertension or heart failure. However, exper-
mental data suggest that ACE inhibition may be deleteri-
us in the setting of primary mitral regurgitation, where
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Legal Regulation of Cardiovascular Drugs December 21, 2004:2285–92ffects on the specific form of extracellular matrix remodel-
ng induced by the drug may potentiate loss of contractility
5). This concern can be resolved only by a clinical trial.
econdly, even when a group of drugs (“class”) shares many
tructural and pharmacologic features, intragroup molecular
ariations, albeit modest, can cause important variations in
harmacologic effects and in dose-response relations for
ifferent effects. For example, different clinical effects have
een discerned among beta-blocking drugs, depending on
hether they manifest intrinsic sympathetic agonist activity,
n their relative selectivity for beta-receptor subtypes, etc.
mong If current blockers now gaining interest as anti-
nginal/anti-ischemic drugs (effect attributed to isolated
eart rate slowing), an early prototype, zatebradine, caused
eversible but unacceptable visual symptoms, presumably
ecause similar ion channels subserve effects in the sino-
trial node and in the retina, whereas another, ivabradine,
as prevented angina with far more modest visual symptoms
6). Thirdly, although it is inviting to ascribe clinical
enefits to specific pharmacologic effects, the perceived basis
f clinical effects changes as fundamental pathophysiology
nd pharmacology are increasingly clarified. For example,
lthough all hydroxymethyl glutaryl coenzyme A reductase
nhibitors (statins) tested to date have been effective in
educing ischemic events and therefore, it has been plausible
o ascribe their effects solely to cholesterol lowering, recent
ata also tend to support the impact of drug-mediated
eduction in plaque inflammatory activity (7,8).
urrogates. Surrogate end points are laboratory tests or
linical measures, such as blood pressure, that are believed to
elate invariably to clinical outcome but are not themselves
linical benefits (4). To be an acceptable basis for drug
pproval, the relation between the surrogate and clinical
utcome must be constant. Surrogates and interventions
ust not interact (i.e., surrogate and clinical outcome both
ust change similarly irrespective of the form of interven-
ion); improvement in the surrogate invariably must lead to
linical benefit. Historically, variations in blood pressure
ave been closely related to variations in the risk of stroke,
ith less clear effects on myocardial infarction and heart
ailure. Also, despite possible differences in some effects of
nterventions noted in the recent Antihypertensive and
ipid-Lowering treatment to prevent Heart Attack Trial
ALLHAT) (9), all interventions that reduce blood pres-
ure, irrespective of pharmacologic class, have had direction-
lly similar effects on events. Consequently, blood pressure
eduction has been accepted as a surrogate for clinical
enefit, and drugs are approved if blood pressure reduction
s demonstrated. An antihypertensive drug could have
dditional benefits (e.g., reduction in rate of deterioration of
enal function in type II diabetics by losartan and irbesartan
ut not by an equi-effective antihypertensive dose of amlo-
ipine) or improvement in some heart failure outcomes by
ertain antihypertensives, but these benefits must be dem-
nstrated directly for approval to be granted for such an
ndication. In contrast to blood pressure, left ventricular gjection fraction for heart failure outcomes, ST-segment
epression on the exercise electrocardiogram (ECG) or on
he 24-h ambulatory ECG, or radionuclide-based measures
f ischemia for ischemic event risk, among other measures,
ave been proposed as surrogates, but have either failed to
anifest an invariant relation between the effect of the
ntervention on the surrogate and on the outcome or have
ot been studied with sufficient interventions to allow
onfidence that such an invariant relation exists. The search
or surrogates continues, driven by the economics of drug
evelopment and the realities of trial conduct. The success
f multi-drug, multi-modality therapy in reducing the risks
rom major cardiovascular diseases requires conducting pro-
ressively larger (and costlier) clinical trials to demonstrate
elatively small but potentially clinically important incre-
ental benefits. Resulting costs increasingly threaten fur-
her therapeutics development.
tudy design: efficacy assessment. Evidence of efficacy
equires a rigorous comparison between a new therapy and
ither no therapy, treatment with an agent already approved
or a similar purpose, or treatment with different doses of
he new agent. Regulations do not specify the form of such
omparisons and allow for nonrandom and even “histori-
ally controlled” trials. However, because of the potential for
nintentional bias and confounding, cardiovascular drug
pprovals are currently based solely on contemporaneous
omparisons using randomized, usually double-blinded
tudy designs. In theory, a clinical entity might have
utcomes sufficiently predictable so that historical controls,
lone, could be used (e.g., anuric renal failure, inevitably
apidly fatal without dialysis); FDA approval of cardiovas-
ular therapies has not been sought for such entities.
owever, although “non-inferiority” trials (discussed sub-
equently) are based on contemporaneous comparison of a
ew treatment with an active control, historical information
ust be employed in defining the extent of non-inferiority
hat must be precluded (it cannot be larger than the effect of
he control).
Several study designs may be appropriate for compari-
ons; selection is based on multiple factors, including the
enefit expected. For example, if symptom reduction is
ought, parallel-arm or cross-over studies might be accept-
ble; the parallel comparison might even come at the end of
period in which all patients received the new treatment
“randomized withdrawal”), a very attractive strategy in
ertain situations (10). If natural history alteration is antic-
pated, only parallel-arm studies may be appropriate.
Data interpretation is least ambiguous when a drug is
ompared with placebo without any background therapy.
owever, in the present era, to achieve requisite population
izes, it may not be possible to maintain placebo therapy
lone for sufficient time to study the drug effects on certain
nd points with adequate statistical power to be likely to
emonstrate a drug effect, even if it truly exists. Therefore,
omparisons with placebo are often carried out with back-
round therapy, sometimes involving several drugs and
v
c
t
p
p
g
f
d
fi
a
n
u
s
f
t
(
c
t
t
w
b
t
t
e
t
i
c
t
o
n
t
v
n
t
i
s
i
i
A
n
(
d
o
G
s
t
c
t
d
i
a
b
a
a
p
s
c
A
t
p
i
c
p
m
t
f
h
e
S
t
i
t
t
e
c
a
(
l
e
w
a
u
w
r
(
d
d
i
p
p
r
t
w
e
p
r
b
c
t
i
i
e
o
w
a
2289JACC Vol. 44, No. 12, 2004 Borer
December 21, 2004:2285–92 Legal Regulation of Cardiovascular Drugsarying among subsets within the population. This may
onfound data interpretation but, given the proliferation of
reatments for many conditions and the ethical and/or
ractical necessity of applying at least some of these, the
roblem is unavoidable. The potential impact of back-
round therapy can be evaluated statistically, albeit imper-
ectly unless background treatment is uniform or study
esigns include complicated (and often impractical) strati-
cation and balancing schemes.
Comparison can be undertaken with a labeled dose of an
pproved drug, aimed at demonstrating superiority of the
ew agent. Although sometimes successful (and providing
nambiguous evidence of effectiveness when it is), this
trategy minimizes the likelihood of demonstrating a benefit
rom the new therapy (11). Therefore, trials can be designed
o demonstrate “non-inferiority” of one regimen to another
i.e., to show that a defined amount of the effect of the
ontrol agent is retained by the new therapy). The effect of
he control agent in the non-inferiority trial is inferred from
he results of earlier trials that compared the control agent
ith placebo.
The FDA has suggested that the acceptable difference
etween a new drug and active comparator should be less
han the difference between the effect of the comparator and
he upper boundary of the confidence interval of the placebo
ffect in the historical comparison; however, other regula-
ory authorities (and the FDA) may allow greater flexibility
n defining “non-inferiority” standards. For optimal appli-
ation, this approach requires an extensive comparison of
he active control and placebo, so that the incremental effect
f the active control is reasonably well defined. Unfortu-
ately, for most approved treatments, the point estimate of
he effect versus placebo has fairly broad confidence inter-
als. Thus, with few exceptions, assumptions underlying
on-inferiority trials involve considerable uncertainty. In
he U.S., an efficacy claim supported solely by non-
nferiority trials would require additional support of some
ort but, as in all other cases, decisions would be importantly
nfluenced by situation-specific data, including confidence
n the anticipated effect of the control versus placebo.
pproval for clopidogrel was based on a single trial in which
on-inferiority was persuasively demonstrated versus aspirin
for which the effect versus placebo was relatively well
efined historically). In this trial, clopidogrel actually dem-
nstrated nominal (p  0.05) superiority to aspirin (12).
enerally, this would be considered insufficient evidence to
upport approval from a single trial (see subsequent Statis-
ics section), but because of the known effect of aspirin,
lopidogrel was judged to be clearly effective (i.e., superior
o placebo).
A comparison of the new agent with itself at different
oses (i.e., demonstration of a dose-response relation)
ndicates drug efficacy if, within the proposed range of
dministration, higher doses cause progressively greater
eneficial effects.
As inferable from the 1997 law, support for the efficacy of snew treatment might result from experience with other
pproved drugs of the same class or with some similar
roperties, perhaps allowing approval based on a single
tudy without a particularly high level of statistical signifi-
ance. During the past three years, the Cardio-Renal
dvisory Committee has suggested on multiple occasions
hat, in most instances, such support is at best modest,
rimarily because of the previously noted arguments favor-
ng direct testing of clinical efficacy rather than extrapolating
linical effects from pharmacologic effects. However, de-
ending on the specific characteristics of the parallel treat-
ents and of the relevant data, outcomes with similar
herapies might affect the strength of evidence expected
rom the primary (pivotal) trials of a new therapy or might
elp justify acceptance of a large single trial demonstrating
ffects considered particularly beneficial.
tudy design: efficacy persistence. Usually it is assumed
hat drug regimens for long-term use (though not necessar-
ly those intended for single, short-duration or repeated
ransient use) will maintain their efficacy indefinitely, al-
hough this presumption has never been tested. To provide
vidence of reasonable effect persistence, drugs aimed at
hronic symptom relief generally must demonstrate efficacy
t least three to six months after treatment initiation
interval depending on the disease); this duration is based
argely on empirical observations on the predictive value of
ffect persistence over this interval and is subject to change
ith new empirical data. The three- to six-month standard
lso is driven by the observation that drugs for long-term
se sometimes do not achieve a maximal effect until many
eeks after initial administration and by the need to allow
easonable exposure for detection of certain types of AEs.
Assessment of efficacy persistence for symptom reduction
and concomitant evaluation for “rebound phenomena,”
iscussed later) is best achieved with randomized with-
rawal from treatment at the conclusion of an appropriate
nterval. This study design feature can be applied after
rolonged open-label active therapy, thus minimizing the
ractical difficulty and costs potentially associated with
andomized, double-blinded comparisons of similar dura-
ion, and can provide persuasive evidence of effectiveness as
ell. For example, for the If current inhibitor, ivabradine,
fficacy in angina prevention was confirmed, and a lack of
harmacologic tolerance or rebound was demonstrated by
andomized withdrawal at the conclusion of a trial that
egan with a two-week, placebo-controlled, parallel-arm
omparison of multiple ivabradine doses, followed by two to
hree months of open-label treatment of all patients receiv-
ng the highest ivabradine dose (6).
For treatments intended to alter survival and/or to min-
mize major morbid events, no specific standard exists for
ffect persistence. The basis for approvability would depend
n the expected natural history of the specific disease,
hether the treatment is intended for application during
cute events or for a chronic condition, as well as on the
pecific benefits and risks expected. In general, for most
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Legal Regulation of Cardiovascular Drugs December 21, 2004:2285–92hronic conditions, evidence of survival improvement
nd/or major morbid event reduction for at least one year is
resented, often including information on many patients
tudied for several years. Generally, there should be no
ubstantial narrowing of the gap between treatment and
omparator during the interval of observation, but this
attern probably reflects the specific nature of the claims
hat have been sought and by expectations of the scientific
ommunity and Advisory Committees and is not mandated
y the FDA.
A related concern is that of rebound phenomena. Unfor-
unate experience 30 years ago revealed that sudden cessa-
ion of short-acting beta-blockers in patients with ischemic
eart disease is associated with a modest risk of myocardial
nfarction or sudden death. Now, some assessment of the
ffect of stopping a drug is expected, specifically to detect
ebound.
afety assessment. Unless special circumstances suggest
he prudence of more intensive scrutiny (concerns based on
undamental pharmacologic properties, adverse findings
rom animal studies, the likelihood of co-administration
ith other drugs that might interact adversely with the new
gent, all of which also might lead to requests for studies in
pecial populations), in accordance with recent international
egulatory harmonization agreements, the Cardio-Renal
ivision expects exposure of at least 1,500 to 2,000 patients
o a new drug product before approval, with 300 to 600
xposed for six months or more and at least 100 patients
xposed for one year or more. Past experience with certain
ypes of treatments may suggest the need for treatment-
pecific safety data for certain outcomes; sometimes these
equirements encompass all drug classes. On the basis of
xtensive empirical evidence linking ECG QT prolongation
ith sudden death and torsade de pointes arrhythmias, the
DA now requires evaluation of potential QT effects of all
ew drugs.
After approval, voluntary physician reports of AEs are
egularly evaluated by the FDA. It is clear that relatively rare
Es, even if catastrophic, could easily be missed with the
equired pre-marketing exposure. However, the exposure
tandard is justified by the perceived balance between the
isk of harm to individuals from missing a serious AE and
he harm to the public from the likelihood that requiring
ubstantially larger and longer pre-marketing exposure
ight suppress development of generally beneficial new
herapies. Empirically, this system is acceptable: relatively
ew drugs have required post-approval withdrawal because
f AEs first recognized after approval.
tatistics. Statistical evidence of a drug-mediated benefit is
xpected to be strong, in accordance with the law. The usual
tandard for each study is statistical confidence that, if
epeated 100 times, efficacy would be found in 95 studies
p  0.05). On the basis of this standard, in the usual case,
f two studies are positive, the likelihood is very low that an
neffective drug will be approved. The FDA has described
vidence that may be considered in judging the persuasive- oess of a single trial but, ultimately, such decisions are
argely based on intuitive judgments. The Cardio-Renal
ivision has suggested that equivalence to two trials might
e inferable if a single trial achieves a p value approximating
hat of p  0.05 in two trials, roughly equivalent to p 
0.05)2/2  0.00125, but several drugs have been approved
n the basis of single trials without achieving quite such a
tringent standard when Advisors and the FDA found the
rials and supporting evidence otherwise compelling. Safety
eeds to be demonstrated by the sponsor; however, no
igorous statistical standard exists to define a lack of safety.
larming clustering of SAEs, without statistical signifi-
ance, can result in withholding approval.
he label. About 20 years ago, a labeling amendment was
equested for short-acting nifedipine that included an indi-
ation for treatment of “hypertensive urgencies.” Three
ears earlier, the drug had been approved for prevention of
ngina due to vasospasm, as well as for typical effort-
nduced angina. Among other reasons, the Advisory Com-
ittee recommended denial of the amendment (the FDA
oncurred) because directions for use were inadequate:
either the proposed label nor the supporting evidence
efined “hypertensive urgency,” the condition for which the
rug would be applied. More recently, a labeling amend-
ent was sought for aspirin, already approved for preven-
ion of ischemic events in patients with established ischemic
eart disease (secondary prevention); the sponsor proposed
he additional indication of event prevention in patients
ithout clinically evident ischemic disease but with a clinical
rofile suggesting 20% event risk over the succeeding 10
ears (primary prevention). Supporting data included mul-
iple placebo-controlled trials (different risk profiles) involv-
ng more than 55,000 patients. No individual trial prespeci-
ed the risk profile envisioned in the new label, and not all
chieved statistical significance for event reduction. How-
ver, the data suggested that: 1) aspirin reduces ischemic
vents across populations of various risk profiles, probably
ncluding persons who would form the newly targeted
opulation; and 2) major bleeding events, including
ransfusion-requiring hemorrhage and hemorrhagic stroke,
ccur with sufficient frequency that a benefit might be
udged to exceed the risk only if the pre-therapy ischemic
vent risk is 2%/year. Advisory Committee concerns
ncluded the difficulty of creating an equation that weighs
isparate benefits and risks appropriately. More impor-
antly, the target population was defined by a Framingham
tudy event risk algorithm that, although intrinsically rea-
onable, had not been applied, even retrospectively, to the
opulations that produced the benefit/risk data presented to
he Committee. The aspirin labeling amendment proposal
xemplifies a fundamental regulatory concern that arises
henever treatments are considered for prevention of events
n asymptomatic patients. In part, such claims are based on
he assumption that, on average, the long-term benefit/risk
elation will be better if treatment is begun before evidence
f disease develops than if applied immediately after non-
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ome patients will die before treatment application. This
ssumption may be correct but was not tested in any of the
rials in which aspirin was studied and seldom is formally
ssessed in other parallel situations. (Conversely, it is also
ossible that treatment primarily prevents early events, in
hich case a therapeutic benefit could be missed if treat-
ent began only after such events had occurred.) The
DA’s approval for a preventive indication has potential
egal as well as public health ramifications based specifically
n the population targeted for drug use in the label.
herefore, considerable rigor should be applied in designing
he supporting studies justifying the targeting of a popula-
ion for labeling.
EVICES AND BIOLOGICALS
he general principles underlying drug approval apply to
evices and biologicals. However, important specific mod-
fications can affect interpretation of data. For example,
andomization to device versus no device may not be
ractical in certain settings, particularly when benefits are
mmediate and obvious, as in angina prevention with
oronary angioplasty or prosthetic valve implantation for
eart failure. Active control studies might detect major
ifferences between devices; however, for more subtle dif-
erences, the number of device insertions performed in the
.S. each year may not provide study populations suffi-
iently large to adequately power either superiority trials of
ew devices versus approved comparators or rigorously
esigned non-inferiority trials during the relatively short
nterval available before engineering upgrades alter the
evice (see subsequent text). Comparative data may not be
eeded for certain important safety data (e.g., device failure
ate), which could be acceptably defined from observational
tudies (e.g., registries). Parenthetically, if a strong consen-
us supports use of already approved devices—like pros-
hetic valves or coronary stents—for reduction in mortality
r major morbid event rates (indications for which random-
zed trials have never been performed), supporting these
laims with well-controlled trials also may be impossible:
andomization may be ethical, but recruitment may be
mpeded by patient and physician bias. Blinding may also be
mpossible for some evaluations. When device (or biologi-
al) insertion/administration involves substantial risk (e.g.,
nvasive procedures), sham administration to enable blind-
ng may not be ethically acceptable. If the device provides
ignals clearly perceptible to the senses (e.g., localized
aresthesias from nerve stimulation), blinding of both pa-
ients and/or evaluators may be impossible. In these situa-
ions, objective outcome measures and other study design
eatures must be carefully selected to minimize the impact of
on-blinding. Device and biological safety concerns differ
omewhat from those of drugs. Most (but not all) nonfatal
rug-induced AEs are reversible with drug cessation. Re-
oval or deactivation of devices and biologicals like genend somatic cell therapies may be dangerous or impossible.
herefore, formal multi-year/multi-decade follow-up is a
ondition of approval, and reporting of major AEs is legally
equired (if not always complete). The FDA can withdraw
pproval and mandate recall if harm is found. For drugs,
nless the form and bioavailability of active principals are
dentical, different formulations of the same drug may
though often do not) require separate efficacy/safety studies
or approval. In contrast, device (and biological) designs are
ften altered during development; a paucity of study popu-
ations and the expectation of such improvements renders
ong-term pre-approval follow-up impractical. As a conse-
uence, statistical evidence supporting approval of devices is
ften less than that expected for drugs, making experienced
udgments particularly crucial.
onclusions. The foregoing has summarized some of the
rinciples underlying regulatory evaluation of therapeutics.
any important issues have not been discussed, including
onsiderations relating to drug or drug-device combina-
ions, selection of end points (particularly if composite),
tatistical concerns relating to “splitting alpha” for multiple
rimary end points, the potential for combining superiority
nd non-inferiority analyses in the same trial, the role of
DA guidance documents, the importance of defining a
ose-response relation from minimally effective to maxi-
ally tolerated doses, the degree of processing that renders
utologous biologicals subject to FDA approval, and others.
owever, most importantly, I hope this account has indi-
ated the intensive effort to achieve scientific rigor, logic,
nd fairness that is central to the process of identifying
ffective and safe therapeutics to guard the public health.
or this, all of us owe the FDA an extraordinary debt.
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